GoodRx Holdings Inc - Class A

NASDAQ: GDRX
$6.50
-$0.02 (-0.3%)
Closing price April 17, 2024
GoodRx Holdings Inc provides a platform that helps consumers in the United States save on prescription drugs. By offering a price comparison tool, GoodRx enables users to find the best prices for their medications, access discounts, and even enjoy additional healthcare services such as telehealth. Founded in 2015 and based in Santa Monica, California, the company simplifies the process of finding affordable prescriptions and healthcare products for millions of people.
Tuesday afternoon's top analyst upgrades and downgrades included Coupa Software, GoodRx, Mosaic and Nektar Therapeutics.
Wednesday's top analyst upgrades and downgrades included Allstate, Arista Networks, Comcast, DraftKings, GoodRx, Kroger, Live Nation Entertainment, Luminar Technologies, Snap, Sunstone Hotel...
Tuesday afternoon's top analyst upgrades and downgrades included Charter Communications, Comcast, Farfetch, GoodRx, Lincoln National and Vroom.
Tuesday afternoon's top analyst upgrades and downgrades included Boot Barn, Cigna, Comerica, GoodRx, Oracle and United Rentals.
Friday’s top analyst upgrades and downgrades included Alphabet, Doximity, IBM, Marriott International, Marvell Technology, Snap, Teladoc Health, TripAdvisor, Twitter, Uber Technologies and Zillow.
Tuesday’s top analyst upgrades and downgrades included Dominion Energy, FireEye, GoodRx, Intuit, Occidental Petroleum, Unity Software and Virgin Galactic.
Monday's top analyst upgrades and downgrades included Darden Restaurants, Foot Locker, Gap, Kellogg, Moderna, Philip Morris International, Prologis, Rockwell Automation and Texas Roadhouse.
Thursday's top analyst upgrades and downgrades included Boeing, Citigroup, Cree, FuelCell Energy, Lowe's Companies, NextEra Energy, Nio, Nvidia, Shopify, Sonos, Square, Target, Uber and Yelp.
Wednesday's top analyst upgrades and downgrades included Baidu, BigCommerce, Boeing, Ciena, Deere, GoodRx, Kohl's, ONEOK, Tesla and Walmart.
The post-IPO quiet period for GoodRx is over, and now analysts are rushing to make calls on the stock. For the most part, sentiment seems relatively positive.